Next Issue

Paul Mattes, Industry Solutions Director, Life Sciences, Microsoft
Leveraging Microsoft compliant, standards-based products and technology: How to assist healthcare and life sciences industries in breaking down information barriers between the disparate IT environments across the pharmaceutical industry and biotechnology.

Rebecca Kush, President, CDISC
CDISC: The Future. In this interview, Rebecca Kush will outline the next 5 years for CDISC, where the organisation is going and what is on the horizon.

Charles Baum, Oncology Therapeutic Area Clinical Head of Pfizer Global Research and Development Pfizer
The company’s route to securing the first European early approval for new kidney cancer drug and the effects of the decision on the industry.

Jerold Grupp, Director, clinical operations support team – J&J
Using IVRS to cut waste in clinical trials.

Andrew Jackson, Deputy Head of Corporate Security Novartis International
The key tools of an effective pharmaceutical anti-counterfeiting strategy: Geographical “hotspots” and results of an aggressive anti-counterfeiting strategy (a counterbalance to so-called technology “solutions”).

Dr Rafik Bishara, Chair, PDA’s Temperature Control Pharmaceuticals Group  (formerly the Pharmaceutical Cold Chain Discussion Group) and former Director, Quality Knowledge Management and Technical Support, Eli Lilly:  
“My Vision for a Global Standard for Cold Chain.” Dr Bishara is one of the world’s leading experts on cold chain. He has recently established the TPG to link European associations with the PDA (Parenteral Drug Association). It is Dr Rafik’s vision that there is a global standard for cold chain. This article will expound his dream and explain why it will benefit the industry.

Joseph Acker, President SOCMA
The joint position paper by SOCMA and EFCG. The position discusses the matter of GMP compliance inspections of foreign active pharmaceutical ingredient manufacturing facilities by the U.S. FDA and corresponding E.U. Medicines Agencies. The paper addresses patient risk, national security and an economic level playing field..

Tassilo Korab, Healthcare Compliance Packaging Council, Europe:
Improving compliance by enhanced packaging design. Tassilo Korab is a senior consultant with Alcoa Flexible Packaging and executive director of the HCPC, Europe.

1. Peter Hug, Global Head, Roche Pharma Partnering:
The importance of partnering strategy. Roche’s pharma partnering arm is leading the way in partnering. Peter Hug will explore best practice in partnering.

2. BTG:
Contract outsourcing. BTG is a company which sources, protects and develops new products, allowing major pharma companies to develop drugs by contract. The article will examine the future of contract outsourcing – rather than buying up bio companies, firms can outsource development as a way of bringing a drug to market more quickly.

Drug Discovery/Development

Prof Steve Homans, University of Leeds, Faculty of Biological Sciences
“A way to reduce the costly and time-consuming search for new drug molecules” and the possible impact on the Pharma industry.
Professor Homans from Leeds’ Faculty of Biological Sciences explains his method for getting exactly the right molecule first time, by looking not just at the physical shape required to fit the target protein but also at the complex dynamics of the interaction.

Regional Focus

Great Britain and Ireland